

MINGSONG TANG

Counsel

Fangda Partners

+86 20 3325 3830

Mingsong.Tang@fangdalaw.com



PRACTICE AREAS

MR. TANG SPECIALIZES IN M&A, PRIVATE EQUITY INVESTMENT, SPECIAL SITUATION INVESTMENT, DOMESTIC AND OVERSEA CAPITAL MARKETS, AND GENERAL CORPORATE AFFAIRS.

REPRESENTATIVE MATTERS AND CASES

M&A, Restructuring and Private Equity Investments

- Represented Pearl River Enterprises Group and Guangzhou State-owned Capital Operation Fund in acquiring JSTI Group (300284) through a stock transfer and private offering
- Represented Fubo Group (03738.HK) in acquiring Particle Culture
- Represented Lvjing Holding (000502) in acquiring a K-12 institution through a share issuance and cash payment
- Represented WeRide (WRD.NASDAQ) in acquiring Muyue Technology
- Represented China Orient in the debt restructuring and stock transfer of Perfect World (002624)
- Represented CBC Group and Yaneng Bio in acquiring an IVD technology company
- Represented White Horse Media in acquiring an outdoor media enterprise
- Represented GF Xinde Fund in investing in a leading industrial 3D printing company
- Represented Cinda Capital and CITIC Financial in investing in several chip companies through secondary funds
- Represented Guangzhou Industrial Investment Fund in investing in a leading domestic chip manufacturer for atomic clocks and a medical institution chain

- Represented companies in their innovative drug development, public opinion monitoring, chip manufacturing, and automotive manufacturing to attract investors such as Sina, Efung Capital, People's Daily, and the National Semiconductor Mega-Fund.

Special Situation Investments

- Represented China Cinda in the bailout project for Xi'an South China City, a subsidiary of South China City Holdings Limited (01668.HK)
- Represented China Cinda in supporting Shenzhen municipal government's asset revitalization of an industrial park project
- Represented China Cinda in a bailout project addressing delisting risks for a listed company
- Represented China Orient in acquiring and restructuring non-performing loans from Shenzhen Kaisa and its affiliates
- Represented China Orient in acquiring and restructuring non-performing loans from Fosun International's (00656.HK) and Shanghai Yuyuan's (600655) subsidiaries
- Advised China Orient and China Cinda on their investments in China CSSC Holdings Limited (600150), Wangfujing Group (600859), and other projects

Domestic and Overseas Capital Markets

- Represented the issuer Bio-Thera (688177) in its listing on the STAR Market of the SSE, its private offering, and its HKSE listing plan
- Represented the underwriters in Jiumaojiu's (09922.HK) main board listing on the HKSE
- Represented affiliates of Fosun International (00656.HK) in its spin-off and A-share listing
- Represented Lizhi FM (LIZI. NASDAQ) in its post-IPO financing including offshore bond issuances
- Represented issuers in domestic or overseas IPO projects across multiple industries, such as supply chain finance, aesthetic medicine, and vehicle maintenance chains

General Corporate Affairs

- Advised on day-to-day operations for GAC Group (601238), China Merchants Port Group (001872), Sun Yat-sen University, Bio-Thera (688177), etc.
- Advised GAC International, Lizhi FM (LIZI.NASDAQ), JMGO, Huya

(HUYA.NYSE), and other companies on cross-border investments, capital operations, employee stock incentives, investor relations, etc.

OTHER INFORMATION

Education

- Peking University, J.D.
- Peking University, LL.M.
- Shandong University, LL.B.

Professional Qualification

- Admitted to practice in the PRC

Professional Background

Before joining Fangda Partners, Mr. Tang worked for several years at another leading domestic law firm.